Infliximab products neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit binding of TNFα with its receptors.

Is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD), Pediatric Crohn's Disease, Ulcerative Colitis, Pediatric Ulcerative Colitis, Rheumatoid Arthritis (in combination with methotrexate), Ankylosing Spondylitis, Psoriatic Arthritis, or Plaque Psoriasis, who have had an inadequate response to conventional therapy.

The recommended dosage of AVSOLA is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active CD.

An infusion reaction was defined in clinical trials as any adverse event occurring during an infusion or within 1 hour after an infusion.

AVSOLA doses >5 mg/kg in moderate or severe heart failure. Previous severe hypersensitivity reaction to infliximab products or any inactive ingredients of AVSOLA or to any murine proteins.

Patients treated with infliximab products are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.